Cancer Center and Research Institute clinics
Return to Locations Search
Address:
2500 North State Street
(inside UMMC Medical Pavilion)
Jackson, MS 39213
Contact Us:
(601) 815-6700
Parking:
Parking is available in front of the Medical Pavilion and in Garage D. Free valet parking is available and encouraged. Look for the Valet signs upon entry to the parking lot.
Parking Information and Interactive Campus Map
Directions:
The UMMC Medical Pavilion is located on our main campus in Jackson. For navigation purposes, use 1410 East Woodrow Wilson, Jackson MS 39216. Upon entry, all patients are encouraged to register for their appointment(s) at the new registration kiosks located in Suite E. Patients will receive a patient pass to use throughout visits. We ask that check-in be completed prior to arrival by using the eCheck-in feature available in the MyChart app. This will expedite the registration process at the kiosks. Pavilion Suite Directory
Our Care Specialties at this location:
- Genetics and Genomics
- Gynecologic Oncology
- Head and Neck Cancers
- Head and Neck Oncology and Endocrine Surgery
- Hematology/Oncology
- Lung Cancers and Mesothelioma
- Melanoma and Skin Cancers
- Neuro-Oncology
- Oncology
- Skin Cancer Surgery
- Speech Language Pathology
- Surgical Oncology and Endocrinology
- Thoracic Surgery
Our Providers who practice at this location:
| Provider | Specialty Keywords | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Mark D. Anderson, MDSpecialties:
Neuro-Oncology, Brain and Central Nervous System Cancers, Neurology
View Practice Locations
Practice Locations:
|
glioblastoma, oncology, neuro-oncology, brain tumor, glioma, tumor, meningioma, glioblastoma, astrocytoma, neuroscience, neurologist, epilepsy, brain | ||||||||
|
Practice Locations:
|
cancer, imrt, radiotherapy, radiosurgery, igrt | ||||||||
Muhammad O. Chohan, MDSpecialties:
Adult Cranial Neurosurgery, Epilepsy, Oncology Neurosurgery, Stereotactic Radiosurgery
View Practice Locations
Practice Locations:
|
cranial, brain, neurosurgeon, skull, seizure, seizures, epileptic, brain cancer, craniopharyngioma, gamma knife, glioma, cyberknife, brain metastases, meningioma | ||||||||
|
Practice Locations:
|
glioblastoma, oncology, neuro-oncology, brain tumor | ||||||||
Pierre E. De Delva, MDSpecialties:
Lung Cancers and Mesothelioma, Thoracic Surgery, Gastrointestinal (GI) Cancers
View Practice Locations
Practice Locations:
|
adenocarcinoma, reflux, GERD, esophagus, achalasia, ribs, thymus, lung, hiatal hernia, cardiothoracic surgeon, chest wall cancers, acid reflux, stomach, abdominal tumor, gastric, upper gi, large intestine, adenocarcinoma, carcinoma, small intestine, colorectal, colon | ||||||||
|
Practice Locations:
|
leukemia, blood disorders, cancer | ||||||||
Truman M. Earl, MDSpecialties:
Transplant Surgery, Liver Transplant, Pancreas, Liver and Bile Duct Cancers, Gastrointestinal (GI) Cancers, Hepatobiliary and Pancreatic Surgery
View Practice Locations
Practice Locations:
|
transplant, organ, pancreas, living donor, heart, liver, dialysis, kidney, liver, small intestine, cholangiocarcinoma, pancreatitis, gallbladder, pancreatic, hepatocellular carcinoma, stomach, abdominal tumor, gastric, upper gi, large intestine, adenocarcinoma, carcinoma, small intestine, colorectal, colon, whipple procedure, pancreas removal, hpb, whipple surgery, whipple operation, pancreas operation, whipple, pancreatitis treatment | ||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
|||||||||
Lana L. Jackson, MDSpecialties:
Head and Neck Cancers, Head and Neck Oncology and Endocrine Surgery
View Practice Locations
Practice Locations:
|
squamous cell carcinoma throat, tongue, squamous cell carcinomas, mass, neck tumor, thyroid, thyroid nodule, parotid blockage, endocrine, voice box, laryngeal cancer, submandibular gland, head cancer, tumors, moles, larynx, melanomas, parathyroidectomy, otolaryngology, lymph node cancer, cancer, tonsil cancer, mouth, otolaryngology surgery, head neck cancer, submandibular blockage, skin, ent, otorhinolaryngology, submandibular stones, lesion, neck throat, parotid infection, throat cancer, throat mass, throat, skin lesion removal, throat cancer surgery, nevi, neck cancer, mouth cancer, neck, lymph nodes, parotid gland, submandibular infection, otorhinolaryngist, otolaryngologist, ear cancer, basal cell, enlarged, parotid mass, neck dissection, thyroid cancer, radical neck dissection, thyroidectomy, parotid stones, neck cancer surgery, ent head neck cancer | ||||||||
Rojymon Jacob, MDSpecialties:
Children's Radiation Oncology, Radiation Oncology
View Practice Locations
Practice Locations:
|
neuroblastoma, rad onc, pediatric radiation oncology, free cme, rad-onc, radiation oncology, children radiation oncology, childrens radiation oncology, pediatric, cancer, imrt, radiotherapy, radiosurgery, igrt | ||||||||
Gina D. Jefferson, MDSpecialties:
Head and Neck Cancers, ENT Facial Plastic and Reconstructive Surgery, Head and Neck Oncology and Endocrine Surgery
View Practice Locations
Practice Locations:
|
squamous cell carcinoma throat, basal cell, moles, parotid gland, submandibular stones, ear cancer, skin, keloid on face, nevi, parotid stones, parotid mass, facial fracture, melanomas, squamous cell carcinomas, facial paralysis repair, submandibular gland, rhinoplasty, parotid blockage, ear, otolaryngology, nasal, zygoma, facial scars, parotid infection, skin cancer defects, nose, cheek, submandibular infection, skin lesion removal, septal deviation, ent facial surgery, ent reconstructive surgery, nasal fracture, submandibular blockage, tongue, squamous cell carcinomas, mass, neck tumor, thyroid, thyroid nodule, parotid blockage, endocrine, voice box, laryngeal cancer, submandibular gland, head cancer, tumors, moles, larynx, melanomas, parathyroidectomy, otolaryngology, lymph node cancer, cancer, tonsil cancer, mouth, otolaryngology surgery, head neck cancer, submandibular blockage, skin, ent, otorhinolaryngology, submandibular stones, lesion, neck throat, parotid infection, throat cancer, throat mass, throat, skin lesion removal, throat cancer surgery, nevi, neck cancer, mouth cancer, neck, lymph nodes, parotid gland, submandibular infection, otorhinolaryngist, otolaryngologist, ear cancer, basal cell, enlarged, parotid mass, neck dissection, thyroid cancer, radical neck dissection, thyroidectomy, parotid stones, neck cancer surgery, ent head neck cancer | ||||||||
Carter P. Milner, MDSpecialties:
Hematology/Oncology, Leukemias, Lymphomas and Myelomas
View Practice Locations
Practice Locations:
|
leukemia, blood disorders, cancer, non-hodgkin's, hodgkin's, cancer | ||||||||
|
Practice Locations:
|
cancer, imrt, radiotherapy, radiosurgery, igrt | ||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
neurosurgeon, vascular, back, head | ||||||||
|
Practice Locations:
|
|||||||||
|
Practice Locations:
|
|||||||||
Prashant Yarlagadda, MDSpecialties:
Children's Radiation Oncology, Radiation Oncology
View Practice Locations
Practice Locations:
|
neuroblastoma, rad onc, pediatric radiation oncology, free cme, rad-onc, radiation oncology, children radiation oncology, childrens radiation oncology, pediatric, cancer, imrt, radiotherapy, radiosurgery, igrt |
Our Clinical Trials offered at this location:
Researchers at UMMC are committed to discovering innovative ways to prevent and treat the diseases that affect our daily lives. Clinical research studies play a vital role in the advancement of medicine and can improve the well-being of our families, friends, communities, and future generations. In this way, participation in clinical research studies furthers our vision to create "a healthier Mississippi."
Partnering with UMMC’s researchers may have many advantages, including:
- Gaining access to investigational treatments
- Increasing knowledge about your own health
- Giving the gift of improved health to our communities and future generations
- Contributing to the advancement of science by helping researchers learn more about how the human body and mind work or by helping find a cure or better treatments for diseases
| Clinical Trials | Publish Date | Description | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
A Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/II A Cervical cancer Treated With Initial Radical Hysterectomy and Pelvic LymphadenectomyIRB Number: 2010-0249
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528153446 |
The purpose of this study is to find out if weekly cisplatin and concurrent radiation therapy increases the time participant's time without disease compared to radiation therapy alone.<br> cancer GOG 263 Maggie Goad Betty H. Melton Cancer |
||||||||
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)IRB Number: 2019-0027
Published: May 29, 2019
View Locations
Clinical Trial Locations:
|
20190529104313 |
The purpose of this study screening step is to test specific genes and proteins in your tumor sample cancer LUNGMAP Jennifer Barnes jruckdeschel Cancer |
||||||||
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological CancersIRB Number: 2024-276
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625164130 |
<div style="box-sizing: border-box; margin-top: 0.5rem; font-weight: 700; font-size: 14px; color: #565c65; padding-bottom: 2px; border-bottom: 1px solid #dfe1e2; margin-bottom: 8px; text-transform: capitalize; font-family: Roboto, sans-serif; background-color: #ffffff;">rief Summary</div><div style="box-sizing: border-box; margin-bottom: 20px; color: #171716; line-height: 1.62; font-family: Roboto, sans-serif; background-color: #ffffff;">IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.</div><div style="box-sizing: border-box; position: relative; width: 743px; flex: 0 1 auto; font-weight: 700; font-size: 14px; color: #565c65; padding-bottom: 2px; border-bottom: 1px solid #dfe1e2; margin-bottom: 8px; text-transform: capitalize; font-family: Roboto, sans-serif; background-color: #ffffff;">Detailed Description</div><div style="box-sizing: border-box; margin-bottom: 20px; color: #171716; line-height: 1.62; font-family: Roboto, sans-serif; background-color: #ffffff;">Participants may continue on study drug based on clinical benefit until disease progression, adverse event (AE) requiring discontinuation, withdrawal of consent, physician decision, or other discontinuation criteria are met.</div> endometrial;ovarian;peritoneal;fallopian;fallopian tube IMGN151-1001 Winona Blount rocconi Cancer Women's Health |
||||||||
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of TherapyIRB Number: 2023-72
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120093557 |
talquetamab, daratumumab, pomalidomide, multiple myeloma, cancer, elkins 64407564MMY3002 Jennifer Barnes Stephanie Elkins Cancer |
||||||||
A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantIRB Number: 2023-111
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120093859 |
<div>The purpose of the study is to evaluate whether elranatamab monotherapy can provide <span style="font-size: 1rem; color: #0a0a0a;">clinical benefit compared to lenalidomide monotherapy (control) in participants with newly </span><span style="font-size: 1rem;">diagnosed multiple myeloma who are MRD-positive after undergoing ASCT.</span></div> elkins, multiple myeloma, cancer, stem cell, elranatamab, lenalidomide C1071007 Jennifer Barnes Stephanie Elkins Cancer |
||||||||
A Phase 3, Randomized, Open Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R CHOP Compared to R CHOP in subjects with Newly Diagnosed Diffuse Large B Cell Lymphoma DLBCL EPCORE DLBCL2IRB Number: UMMC-IRB-2024-26
Published: March 25, 2024
View Locations
Clinical Trial Locations:
|
20240325105949 |
The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R CHOP followed by 2 cycles of epcoritamab can prolong progression free survival (PFS) compared with 6 cycles of standard R CHOP alone followed by 2 cycles of rituximab in subjects with newly diagnosed DLBCL with an IPI of 3 to 5. cancer, elkins, r chop, lymphoma M20-621 Jennifer Barnes Stephanie Elkins Cancer |
||||||||
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at SurgeryIRB Number: 2024-276
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625165217 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.</span> 2870-012;tnbc;breast;breast cancer;triple negative breast neoplasms;triple negative breast cancer MK2870-012 Winona Blount bcraft Cancer Women's Health |
||||||||
A Phase 3b, Multi-center, Randomized, Double-blind, Placebo controlled, Parallel-group Trial with an Open-label Extension Phase to demonstrate that the efficacy of avatrombopag is superior to placebo for the treatment of pediatric subjects with ITP of ≥6 months duration who have had an insufficient response to a previous treatment.IRB Number: 2020V0152
Published: October 20, 2021
View Locations
Clinical Trial Locations:
|
20211020143313 |
This Phase 3b, multi-center, randomized, double-blind, placebo-controlled, parallel-group study in pediatric subjects who have had a diagnosis of ITP for ≥6 months, includes a 12 week Core Phase followed by a 2 year open-label Extension Phase. pediatrics AVA-PED-301 Rhonda Aikens ddavis7 Pediatrics |
||||||||
A Phase I, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancerIRB Number: 2021-0541
Published: September 14, 2023
View Locations
Clinical Trial Locations:
|
20230914075648 |
The purpose of this study is to evaluate OBT076, a drug that combines an antibody with the anti-cancer drug. This study will look at several dose levels of the study drug to find out the highest does level that is safe and well-tolerated and to look at the side effects of the study drug in a small group of people. OBT076 is experimental.<div><br></div> tang;obto076-001;cancer;recurrent cancer;metastatic cancer OBT076-001 Jennifer Barnes John Henegan Cancer |
||||||||
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk FeaturesIRB Number: 2021-0520
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327124639 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.</span> head;head and neck;neck;cancer;morgan EA3191 Winona Blount dpmorgan Cancer Neurosciences |
||||||||
A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)IRB Number: 2022-459
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325173703 |
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma. prcc;rcc;cancer;henegan;kidney cancer S2200 Winona Blount jhenegan Cancer Kidney/Renal Conditions |
||||||||
A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).IRB Number: 2022-459
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120110550 |
<span style="color: #171716; font-family: Roboto, sans-serif; font-size: 16px; background-color: #ffffff;">This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.</span> henegan, cancer, cabozantinib, atezolizumab, advanced papillary renal cell carcinoma, papmet2 S2200 Jennifer Barnes John Henegan Cancer |
||||||||
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)IRB Number: 2019-0132
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325150150 |
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. genitourinary;cancer;henegan A031702 Winona Blount jhenegan Cancer |
||||||||
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyIRB Number: 2021-0584
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325162803 |
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer. bladder;urothelial cancer;henegan S1937 Winona Blount jhenegan Cancer |
||||||||
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)IRB Number: 2022-0657
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120091637 |
muscle, muscle invasive, bladder cancer, cancer, henegan, astrazeneca D910PC00001 Jennifer Barnes John Henegan Cancer |
||||||||
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate CancerIRB Number: 2023-333
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162037 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.</span> henegan;prostate;prostate cancer;cancer CAAA617A12402 Winona Blount jhenegan Cancer Men's Health |
||||||||
A Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast CancerIRB Number: 2018-0183
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151931 |
The purpose of this study is to test whether Carvedilol (Coreg) can reduce the occurrence of heart problems during cancer treatment. <br> cancer S1501 Jennifer Barnes bcraft Cancer |
||||||||
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaIRB Number: 2025-127
Published: October 29, 2025
View Locations
Clinical Trial Locations:
|
20251029173919 |
<div style="box-sizing: border-box; margin-bottom: 20px; color: #171716; line-height: 1.62; font-family: Roboto, sans-serif; background-color: #ffffff;">The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.</div><div><br></div><div style="box-sizing: border-box; color: #1b1b1b; font-family: Roboto, sans-serif; background-color: #ffffff;"></div> unresectable hepatocellular carcinoma;locally advanced hepatocellular carcinoma;metastatic hepatocellular carcinoma;carcinoma;adenocarcinoma CHS-388-202 Winona Blount dpmorgan Liver Diseases Cancer |
||||||||
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)IRB Number: 2023-413
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162940 |
<div style="position: relative; color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"><div style="overflow-y: hidden;">This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.</div><div><br></div></div><a href="https://clinicaltrials.gov/#"></a> morgan;nsclc;non-small cell lung cancer;cancer;lung;non small cell lung cancer S1900G Winona Blount dpmorgan Cancer Lungs/Breathing |
||||||||
A RANDOMIZED PHASE III TRIAL COMPARING ACTIVE SYMPTOM MONITORING PLUS PATIENT EDUCATION VERSUS PATIENT EDUCATION ALONE TO IMPROVE PERSISTENCE WITH ENDOCRINE THERAPY IN YOUNG WOMEN WITH STAGE I-III BREAST CANCER (ASPEN)IRB Number: 2022-69
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120105244 |
<div>To compare persistence with the initially prescribed oral endocrine therapy (ET) <span style="font-size: 1rem; color: #0a0a0a;">through 72 weeks for young women being treated for hormone-receptor positive </span><span style="font-size: 1rem;">stage I-III breast cancer randomized to Active Symptom Monitoring (ASM) + </span><span style="font-size: 1rem;">patient education or patient education alone.</span></div> breast cancer, cancer, craft, endocrine, endocrine therapy S2010 Jennifer Barnes Barbara Craft Cancer |
||||||||
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantIRB Number: 2019-0212
Published: September 24, 2019
View Locations
Clinical Trial Locations:
|
20190924092657 |
The purpose of this study is to find out whether treatment with daratumumab and lenalidomide improves disease response in Multiple Myeloma. cancer;bone marrow transplant l 54767414MMY3021 Jennifer Barnes selkins Cancer |
||||||||
A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATIONIRB Number: 2023-111
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327135600 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years</span> myeloma;multiple myeloma;elkins C1071007 Winona Blount selkins Cancer |
||||||||
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)IRB Number: 2019-0119
Published: June 24, 2019
View Locations
Clinical Trial Locations:
|
20190624133128 |
<div><div>-To determine the RP3R of Canakinumab in combination with pembrolizumab plus platinum-based doublet chemotherapy.</div><div>-To compare patient free survival by local investigator assessment and overall survival between the two treatment arms. </div><div>-To assess the preliminary clinical anti-tumor activity of canakinumab in combination with pembrolizumab plus platinum-based doublet chemotherapy. </div><div>-To characterize the safety and tolerability of canakinumab in combination with pembrolizumab plus platinum-based doublet chemotherapy. </div><div>-To characterize the pharmacokinetics of canakinumab in combination with pembrolizumab plus platinum-based doublet chemotherapy. </div></div> cancer;lungs CACZ885U2301 Jennifer Barnes jruckdeschel Cancer Lungs/Breathing |
||||||||
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyIRB Number: 2025-58
Published: November 06, 2025
View Locations
Clinical Trial Locations:
|
20251106100619 |
<p>The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).</p><p>The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).</p> gog-3104;endometrial;endometrial cancer;sacituzumab;sacituzumab govitecan-hziy;doxorubicin;paclitaxel;uterine neoplasms;gog 3104;engot-en26;ascent-gyn-01 GS-US-682-6769 Winona Blount rocconi Cancer Women's Health |
||||||||
A Study Comparing Perioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)IRB Number: 2019-0009
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133424 |
The purpose of this study is to compare any good and bad effects of using nivolumab before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring.<br> cancer;surgery EA8143 Jennifer Barnes jhenegan Cancer Surgery |
||||||||
A Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk MelanomaIRB Number: 2019-0023
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133618 |
The purpose of this study is to determine if receiving the study drug pembrolizumab before and after surgery or only at surgery is better, the same or worse than usual treatment after surgery. <br> cancer S1801 Jennifer Barnes kjeanes Cancer |
||||||||
A Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerIRB Number: 2017-0109
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152643 |
The purpose of this study is to research the effects, good or bad of Ateozolizumab on ovarian, fallopian tube, or primary peritoneal cancer. <br> women's health;cancer GOG 3015/YO39523 Jennifer Barnes mridgway Cancer Women's Health |
||||||||
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancerIRB Number: 2020-0197
Published: December 21, 2020
View Locations
Clinical Trial Locations:
|
20201221153205 |
<div>To assess the safety of ASG-22CE for the treatment of urothelial cancer</div> cancer SGN22E-002 Jennifer Barnes jhenegan Cancer |
||||||||
A Study of Erlotinib vs Observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer(NSCLC)IRB Number: 2015-0238
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528153155 |
The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. <br> cancer A081105 Jennifer Barnes jruckdeschel Cancer |
||||||||
A Study of Intravenous PI3K Inhibitor Copanlisib in Combination with Standard Immunochemotherapy versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-4IRB Number: 2017-0313
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528145644 |
The purpose of this study is to evaluate the efficacy and safety of the study drug Copanlisib in combination with standard chemotherapy.<br> cancer BAY 80-6946 / 17833 Lisa Freeman selkins Cancer |
||||||||
A Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung CancersIRB Number: 2016-0250
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152727 |
The purpose of this study is to find if adding the study drug, Nivolumab will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.<br> cancer EA5142 Jennifer Barnes JRuckdeschel Cancer |
||||||||
A Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)IRB Number: 2017-0301
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528145159 |
The purpose of this study is to obtain information on the safety and effectiveness of NovoTTF-100M (study device) in subjects with brain metastases (tumors) as a result of non-small cell lung cancer. <br> cancer;lungs;breathing EF-25 Jennifer Barnes manderson4 Cancer Lungs/Breathing |
||||||||
A Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)IRB Number: 2016-0179
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152905 |
The purpose of the Phase II part of the study is to compare any good and bad effects of using a combination of the experimental drugs cediranib and olaparib, to using the standard chemotherapy, or cediranib alone, or olaparib alone. The Phase III study will follow the Phase II to confirm the effectiveness of a combination of cediranib and olaparib to the standard chemotherapy. <br> cancer NRG-GY005 Jennifer Barnes kjeanes Cancer |
||||||||
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed By Tislelizumab Monotherapy in Newly Diagnosed, State III Subjects with Locally Advanced, Unresectable Non-Small Cell Lung CancerIRB Number: 2019-0064
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528113857 |
The purpose of this study is to see whether combining the study drug with chemotherapy and radiation is more effective in treating Non Small Cell Lung Cancer compared to chemotherapy and radiation alone.<br> cancer;lungs BGB-A317-NSCL-001 Jennifer Barnes jruckdeschel Cancer Lungs/Breathing |
||||||||
A Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast CancerIRB Number: 2017-0144
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152542 |
The purpose of this study is to determine whether or not the higher risk for breast cancer recurrence in women who are overweight or obese when they are diagnosed with breast cancer could be reduced or eliminated if weight is lost.<br> cancer;women's health A011401 Jennifer Barnes bcraft Cancer Women's Health |
||||||||
A Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinIRB Number: 2015-0239
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528153122 |
The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes.<br> cancer E4512 Jennifer Barnes jruckdeschel Cancer |
||||||||
A Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant DocetaxelIRB Number: 2018-0146
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151728 |
The purpose of this research study is to learn about the effects of the study drug Docetaxel, when given in combination with radiation therapy and hormone suppression therapy versus when using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.<br> cancer NRG-GU002 Jennifer Barnes jhenegan Cancer |
||||||||
A Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaIRB Number: 2018-0173
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151834 |
The purpose this study is to compare any good and bad effects of using Ramucirumab along with the usual chemotherapy combination (Carboplatin and Paclitaxel) to the usual chemotherapy combination alone. <br> cancer S1701 Jennifer Barnes jruckdeschel Cancer |
||||||||
A Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or without Brain MetastasesIRB Number: 2017-0114
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152622 |
The study is to compare the good or bad effects of using the experimental drug ABT-888 (Veliparib) along with cisplatin to using cisplatin alone. The combination of the 2 drugs could shrink your cancer but could also cause side effects. This study will allow researchers to know whether this different approach is better, the same, or worse than the usual approach of chemotherapy.<br> cancer S1416 Jennifer Barnes bcraft Cancer |
||||||||
A Trial of Nivolumab + Brentuximab Vedotin for Children, Adolescents, and Young Adults with Relapsed/Refractory CD30+ classic Hodgkin Lymphoma after Failure of First-Line Therapy, followed by Brentuximab + Bendamustine for Participants with Suboptimal ResponseIRB Number: 2017-0165
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152157 |
This study is being done to look at the response rate and tolerability of nivolumab + brentuximab vedotin in patients with relapsed/refractory CD30+ classic Hodgkin Lymphoma after failure of first-line therapy. The study will also look at the response rate and tolerability of brentuximab + bendamustine in patients with suboptimal response to nivolumab + brentuximab therapy on this study.<br> cancer;pediatrics CA209744 Maggie Goad Betty H Melton Cancer Pediatrics |
||||||||
A Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal CancerIRB Number: 2019-0063
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133402 |
The purpose of this study is to compare any good or bad effects of adding triapine to the usual cisplatin chemotherapy and radiation therapy, compared to using cisplatin chemotherapy and radiation therapy alone.<br> cancer NRG-GY006 Jennifer Barnes mridgway Cancer |
||||||||
A Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 MutationsIRB Number: 2016-0059
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528153052 |
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes and also to see if tumor genetic testing would be helpful at guiding treatment in patients .<br> cancer A071401 Takila Keys rlong Cancer |
||||||||
A Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate CancerIRB Number: 2018-0200
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133737 |
The purpose of this study is to research the effects, good or bad of adding either radiation therapy or adding surgery to the standard systemic therapy. <br> cancer S1802 Jennifer Barnes JHENEGAN Cancer |
||||||||
A Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and NeckIRB Number: 2014-0215
Published: May 29, 2019
View Locations
Clinical Trial Locations:
|
20190529082618 |
The purpose of the Phase II part of this study is to find out what effects, good and/or bad, one of the following treatments has on participants and their cancer: (Standard treatment) radiation therapy and cisplatin; (Experimental treatment) radiation therapy and docetaxel; or (Experimental treatment) radiation therapy, docetaxel, and cetuximab. The Phase III part of the study will compare the effects, good or bad, of the standard treatment (radiation and cisplatin) to one of the experimental arms (to be determined after completion of the Phase II part of the study) to find out which works best.<br> cancer RTOG 1216 Jennifer Barnes mkanakamedala Cancer |
||||||||
A031702 (ICONIC): A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary CancersIRB Number: 2019-0132
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630093035 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to see how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread to other places in the body.</span> cabozantinib;nivolumab;ipilimumab;iconic;genitourinary (gu) A031702 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]IRB Number: 2019-0147
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630095647 |
The purpose of this study is to compare the usual treatment (Ipilimumab and Nivolumab followed by Nivolumab alone) to treatment with Ipilimumab and Nivolumab with Cabozantinib in patient with untreated renal cell carcinoma that has spread to other parts of the body. pdigree;kidney cancer;nivolumab;cabozantinib A031704 Eulisa Goins-Freeman jhenegan Cancer Kidney/Renal Conditions |
||||||||
Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus ObservationIRB Number: 2018-0191
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528144231 |
The purpose of this study is to compare the good or bad effects of using MK-3475 after the removal of muscle invasive bladder cancer.<br> cancer A031501 Jennifer Barnes jhenegan Cancer |
||||||||
ALCHEMIST - A081105: Randomized Study of Erlotinib vs Observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer(NSCLC)IRB Number: 2015-0238
Published: July 30, 2019
View Locations
Clinical Trial Locations:
|
20190730161507 |
The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. cancer;lungs A081105 Jennifer Barnes jruckdeschel Cancer Lungs/Breathing |
||||||||
ALCHEMIST - A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) A screening trial for A081105 and E4512IRB Number: 2015-0219
Published: July 30, 2019
View Locations
Clinical Trial Locations:
|
20190730155844 |
The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. cancer;lungs A151216 Jennifer Barnes jruckdeschel Cancer Lungs/Breathing |
||||||||
An Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)IRB Number: 2017-0130
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528152559 |
The study will compare three experimental drugs, crizotinib, cabozantinib and savolitinib to the standard treatment of sunitinib in the treatment of advanced kidney cancer. <br> cancer S1500 Jennifer Barnes jhenegan Cancer |
||||||||
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromasIRB Number: 2019-0185
Published: June 17, 2020
View Locations
Clinical Trial Locations:
|
20200617112859 |
The purpose of this protocol is to provide potential treatment of neurofibromatosis type 1 (NF1) with progressive/symptomatic plexiform neurofibromas (PN), by using the study drug, Selumetinib. pediatrics;neuroscience;cancer D1346R00002 Jennifer Barnes manderson4 Cancer Neurosciences Pediatrics |
||||||||
An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBMIRB Number: 2019-0171
Published: June 17, 2020
View Locations
Clinical Trial Locations:
|
20200617135035 |
The purpose of this research is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatments improve overall survival as compared to standard treatments. brain;cancer;neuroscience GCAR-7213 Bridgett Sessions manderson4 Cancer Neurosciences |
||||||||
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPYIRB Number: 2024-204
Published: July 10, 2025
View Locations
Clinical Trial Locations:
|
20250710154527 |
<div>The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body.</div><div><br></div><div>This study is seeking female and male participants who:</div><div><br></div><div>are 18 years of age or older;</div><div>are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative;</div><div>have advanced or metastatic breast cancer after taking other treatments before this study;</div><div>have not taken or need to take medications that are not allowed by the study protocol;</div><div>do not have any medical or mental conditions that may increase the risk of study participation.</div><div>Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be:</div><div><br></div><div>Fulvestrant alone taken as shot into the muscle.</div><div>Everolimus along with exemestane taken once daily by mouth.</div><div>This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective.</div><div><br></div><div>Participants will receive study treatment and/or will be in the study until:</div><div><br></div><div>imaging scans (such as an MRI and/or CT) show that their cancer is getting worse.</div><div>the study doctor thinks the participant is no longer benefitting from the study medicine.</div><div>has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take.</div><div>the participant chooses to stop taking part.</div> fourlight-1;breast;breast cancer;pf-07220060;cdk4 inhibitor;fulvestrant;breast tumor;metastatic breast cancer C4391022 Winona Blount bcraft Cancer |
||||||||
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid TumorsIRB Number: 2025-139
Published: January 08, 2026
View Locations
Clinical Trial Locations:
|
20260108130105 |
<div style="box-sizing: border-box; margin-bottom: 20px; color: #171716; line-height: 1.62; font-family: Roboto, sans-serif; background-color: #ffffff;"><div style="box-sizing: border-box; margin-bottom: 20px; line-height: 1.62;">The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).</div><div><br></div></div> phase 1;phase 2;neoplasms;carcinoma;hepatocellular;liver neoplasms;colorectal neoplasms;endometrial neoplasms E7386-J081-102 Winona Blount rocconi Cancer |
||||||||
ATrial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant ChemotherapyIRB Number: 2016-0069
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528153021 |
The purpose of the study is to determine if radiation treatment to axillary (armpit) lymph nodes (undissected) and regional lymph nodes is as good as axillary lymph node dissection and only regional lymph node radiation therapy in invasive breast cancer patients with positive sentinel lymph nodes after completion of neoadjuvant chemotherapy. <br> cancer A011202 Jennifer Barnes bcraft Cancer |
||||||||
Avastin plus Chemotherapy versus Avastin plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Platinum-Resistant or –Sensitive Epithelial Ovarian, Fallopian tube, or Primary Peritoneal Cancer (ACSCO trial)IRB Number: 2018-0147
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151746 |
The purpose of this study is to screen chemotherapy drugs currently used for the care of recurrent ovarian cancer and to determine the most effective treatment based on results from a chemosensitivity assay.<br> cancer ChemoID Jennifer Barnes kjeanes Cancer |
||||||||
Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)IRB Number: 2015-0234
Published: May 29, 2019
View Locations
Clinical Trial Locations:
|
20190529083048 |
The purpose of this study screening step is to perform tests on genes and proteins produced by genes in tumor samples for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer.<br> cancer S1400 Jennifer Barnes kjeanes Cancer |
||||||||
C16-170 (IRONMAN): International Registry for Men with Advanced Prostate CancerIRB Number: 2020-0161
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630095849 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 15px; background-color: #ffffff;">The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. </span><span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 15px; background-color: #ffffff;">Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed for overall survival, clinically significant adverse events, comorbidities, and changes in cancer treatments.</span> prostate cancer;patient registry;ironman C16-170 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 TrialIRB Number: 2018-0192
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528144214 |
The purpose of this study is compare the good and bad effects of using Cabazitaxel with the usual approach of the hormone based therapy Abiraterone Acteate in combination with Prednisone on patients with advance prostate cancer that have already undergone treatment with hormone therapy and docetaxel. <br> cancer EA8153 Jennifer Barnes jhenegan Cancer |
||||||||
CIBI322A102: A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumorsIRB Number: 2020-0283
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630101603 |
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of IBI322 in cancer patients who failed standard treatment. CIBI322A102 Jessie Solise stang Cancer |
||||||||
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseIRB Number: 2023-265
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625161533 |
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer. cancer;colon;colon cancer;wilkinson NRG-GI008 Winona Blount kjeanes Cancer Digestive Conditions |
||||||||
D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth SalvageIRB Number: 2021-0596
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630102144 |
The purpose of this study is to compare the rate of complete response (CR) and duration of CR, in patients with relapsed or refractory AML to two, three, and four prior inductions regimens that my have included intensive chemotherapy, who will receive DFP-10917 versus non-intensive reinduction or intensive re-induction as a second, third, and fourth salvage treatment. aml;leukemia D18-11141 Eulisa Goins-Freeman selkins Cancer |
||||||||
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsIRB Number: 2017-0152
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528150138 |
This is a study for rare cancers for which there is no standard of care or that has become worse with treatment. The purpose of this study is to determine what good and/or bad effects the combination of the study drugs, ipilimumab and nivolumab, have in the treatment of rare cancers and cancers of unknown primary origin.<br> women's health;cancer S1609 Jennifer Barnes kjeanes Cancer Women's Health |
||||||||
EA1181: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete responseIRB Number: 2020-0136
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630102517 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to see how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy.</span> her2 positive, compasserher2-pcr, breast cancer EA1181 Jessie Solise stang Cancer |
||||||||
EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 SequencingIRB Number: 2020-0086
Published: June 30, 2022
View Locations
Clinical Trial Locations:
|
20220630105541 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to see how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery.</span> head and neck;squamous cell carcinoma;imrt EA3132 Eulisa Goins-Freeman rhamilton Cancer |
||||||||
EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk FeaturesIRB Number: 2021-0520
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712220204 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">Study the effect of pembrolizumab in combination with radiation therapy or pembrolizumab alone compared to the usual approach (chemotherapy plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary).</span> head and neck cancer;pembrolizumab;cancer EA3191 Eulisa Goins-Freeman rhamilton Cancer |
||||||||
EA8191 (INDICATE): Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical RecurrenceIRB Number: 2020-0336
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712215956 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">This study compares the addition of apalutamide, with or without targeted radiation therapy, to standard of care treatment versus standard of care treatment alone in patients with prostate cancer biochemical recurrence (a rise in the blood level of prostate-specific antigen [PSA] after treatment with surgery or radiation). </span> indicate;prostate cancer EA8191 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
EAY131 (MATCH): Molecular Analysis for Therapy Choice (MATCH)IRB Number: 2019-0241
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712215700 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to see how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.</span> eay131;match EAY131 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
ECHO: Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical StudyIRB Number: 2023-353
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162309 |
<p>The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.</p><p>This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma and tampon-collected vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.</p> cancer;ovarian;endometrial;cervical;rocconi ECHO Winona Blount rocconi Cancer Women's Health |
||||||||
EF-32 A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed GlioblastomaIRB Number: UMMC-IRB -2022-78
Published: October 10, 2022
View Locations
Clinical Trial Locations:
|
20221010155958 |
The purpose of the study is to test if early addition of the Optune treatment concomitant with RT and temozolomide as treatment for newly diagnosed GBM, significantly improves the clinical outcome of patients, compared to the standard of care, which is addition of Optune treatment concomitant with maintenance temozolomide after the completion of RT treatment. gbm;trident;optune;2021v0794 EF-32 Lynnette Harper manderson4 Cancer |
||||||||
Evaluation of the Safety and Effectiveness of the GORE® Tissue Reinforcement for Breast Reconstruction Device (TRBR Device) When Used in the Reinforcement of Breast ReconstructionIRB Number: 2024-329
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625105700 |
<div style="box-sizing: border-box; margin-bottom: 20px; color: #171716; line-height: 1.62; font-family: Roboto, sans-serif; background-color: #ffffff;">The GORE Tissue Reinforcement for Breast Reconstruction (TRBR) research study will look at breast reconstruction during mastectomy procedures. There will be two arms in this study, a Treatment Arm, where data will be collected for a new medical device called the Tissue Reinforcement for Breast Reconstruction (TRBR) Device and a Control Arm where data will be collected from subjects who have previously had surgery and received no additional tissue reinforcement in their breast reconstruction surgery. This research study will look at the safety of the Study Device and the success of the participants breast reconstruction. The Study Device is investigational, which means it has not yet been used nor approved by the FDA for this treatment. The data collected in this study will be compared to the data collected in the Control Arm.</div><div><br></div><div style="box-sizing: border-box; color: #1b1b1b; font-family: Roboto, sans-serif; background-color: #ffffff;"></div> breast reconstruction;post-mastectomy;tissue expander;implant based breast reconstruction;two-stage;breast cancer TBR 22-07 Eldrin Bhanat bmcintyre Cancer Women's Health |
||||||||
Genomically-Guided Treatment Trial in Brain MetastasesIRB Number: 2019-0259
Published: March 24, 2025
View Locations
Clinical Trial Locations:
|
20250324134539 |
<div>This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.</div><div><br></div> brain;cancer;matastases;anderson A071701 Winona Blount manderson4 Cancer Neurosciences |
||||||||
GOG 0263 A Randomized phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/II A Cervical cancer Treated With Initial Radical Hysterectomy and Pelvic LymphadenectomyIRB Number: 2010-0249
Published: July 30, 2019
View Locations
Clinical Trial Locations:
|
20190730154229 |
The purpose of this study is to find out if weekly cisplatin and concurrent radiation therapy increases the time participant's time without disease compared to radiation therapy alone. cancer GOG 0263 Jennifer Barnes kjeanes Cancer |
||||||||
INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC: ALCHEMIST CHEMO-IO (ACCIO)IRB Number: 2021-0643
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120105857 |
non-small cell lung cancer, cancer, lung cancer, A081801 Jennifer Barnes Dennis Morgan Cancer |
||||||||
International Registry for Men With Advanced Prostate Cancer (IRONMAN)IRB Number: 2020-0161
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325160016 |
<div>Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.</div><div><br></div><div>Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.</div><div><br></div><div>PROMs questionnaires will be collected at enrollment and every three months thereafter.</div><div><br></div><div>Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.</div><div><br></div><div>As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.</div> ironman;prostate;prostate cancer c16-170 Winona Blount jhenegan Cancer Men's Health |
||||||||
LAE205INT3101: A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care TherapiesIRB Number: UMMC-IRB-2022-87
Published: July 13, 2022
View Locations
Clinical Trial Locations:
|
20220713120151 |
This purpose of this study is to find out if a new investigational drug Afuresertib in combination with Fulvestrant helps you better than Fulvestrant alone. breast cancer;her2 negative;afuresertib;theradex LAE205INT3101 Jessie Solise stang Cancer |
||||||||
LEAHRN (Late Effects After High-Risk Neuroblastoma) StudyIRB Number: 2017-0256
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151434 |
This study aims to evaluate the long term effects that modern therapy for high risk neuroblastoma has on long term survivors. <br> cancer;pediatrics ALTE15N2 Rachel Lowery Betty H. Melton Cancer Pediatrics |
||||||||
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)IRB Number: 2019-0027
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327142640 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.</span> nsclc;morgan;non-small cell lung cancer;non small cell lung cancer;cancer LUNGMAP Winona Blount dpmorgan Cancer Lungs/Breathing |
||||||||
MK-6482-11 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 TherapyIRB Number: 2020V0409
Published: March 31, 2022
View Locations
Clinical Trial Locations:
|
20220331170522 |
The purpose of this study is to test KM-6482 plus Lenvatinib in people with a type of kidney cancer called advanced clear cell Renal Cell Carcinoma (ccRCC). renal cell carcinoma;kidney cancer 011-00 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerIRB Number: 2024-60
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162102 |
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of bladder cancer patients who have undergone surgical removal of their bladder. urothelial carcinoma;cancer;urothelial cancer;henegan;bladder;genitourinary A032103 Winona Blount jhenegan Cancer |
||||||||
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)IRB Number: 2022-0460
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625163122 |
<span style="color: #171716; font-family: Roboto, sans-serif; font-size: 14px; background-color: #ffffff;">This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.</span> small-cell lung cancer, cancer, mundra, lung cancer;small cell lung cancer S1827 Winona Blount EMundra Cancer Lungs/Breathing |
||||||||
NRG GU007: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)IRB Number: 2019-0199
Published: June 15, 2022
View Locations
Clinical Trial Locations:
|
20220615120054 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to study the side effects and determine the best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). </span> prostate cancer;nadir;niraparib NRG GU007 Eulisa Goins-Freeman JHENEGAN Cancer |
||||||||
NRG-BN009: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/YearIRB Number: 2021-0613
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712221545 |
<span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery.</span> non-small cell lung cancer;melanoma;breast cancer NRG-BN009 Jennifer Barnes Mark Anderson Cancer |
||||||||
NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial CancerIRB Number: 2019-0227
Published: June 15, 2022
View Locations
Clinical Trial Locations:
|
20220615123907 |
<div>The purpose of this study is to see how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).</div> gy018;endometrial cancer;pembrolizumab NRG GY0018 Cameronne Dodd kjeanes Cancer |
||||||||
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor TherapyIRB Number: 2023-267
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625155946 |
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab. breast cancer;tnbc;craft A012103 Winona Blount bcraft Cancer |
||||||||
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)IRB Number: 2023-67
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120110906 |
<span style="color: #171716; font-family: Roboto, sans-serif; font-size: 16px; background-color: #ffffff;">This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.</span> cancer, prostate cancer, radiation, predict-rt, henegan NRG-GU009 Jennifer Barnes John Henegan Cancer |
||||||||
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)IRB Number: 2023-67
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327092650 |
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score. henegan;prostate;prostate cancer;cancer NRG-GU009 Winona Blount jhenegan Cancer Men's Health |
||||||||
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway MutationsIRB Number: 2016-0059
Published: March 24, 2025
View Locations
Clinical Trial Locations:
|
20250324134408 |
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. intracranial meningioma;recurrent meningioma;nf2 gene mutation;meningioma;cancer;anderson A071401 Winona Blount MAnderson4 Cancer Neurosciences |
||||||||
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth SalvageIRB Number: 2022-115
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120092609 |
<p>This study will investigate
whether a new experimental treatment, DFP‑10917, will be an effective and safe
treatment option for patients with relapsed/refractory acute myelogenous
leukemia (AML). This is a “randomized” study. If
it is determined during screening that you are eligible for the study, you will
be “randomized” by a computer to receive either DFP-10917 (the experimental
group) or standard treatment (control group) by chance. Neither you nor your
study doctor can choose the group you will be in.</p> cancer, acute myelogenous leukemia, aml, cancer D18-11141 Jennifer Barnes Stephanie Elkins Cancer |
||||||||
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate CancerIRB Number: 2018-0200
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325130622 |
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. prostate;prostate cancer;cancer;henegan S1802 Winona Blount jhenegan Cancer Men's Health |
||||||||
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)IRB Number: 2021-1029
Published: April 28, 2022
View Locations
Clinical Trial Locations:
|
20220428161745 |
The purpose of this study is to see if investigational drug trastuzumab deruxtecan, either alone or in combination with another medication, pertuzumab, is effective in treating patients with Human epidermal growth factor receptor 2 (HER2) positive breast cancer as a first line of treatment. Study will also allow us to better understand the studies disease and associated health problems. destiny;tang;breast09 D967UC00001 Jessie Solise Barbara Craft Cancer |
||||||||
Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)IRB Number: 2023-261
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625161806 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.</span> rcc;kidney;kidney cancer;cancer;henegan S1931 Winona Blount jhenegan Cancer Kidney/Renal Conditions |
||||||||
PHASE III TRIAL OF OBSERVATION VERSUS IRRADIATION FOR A GROSS TOTALLY RESECTED GRADE II MENINGIOMAIRB Number: 2018-0179
Published: June 17, 2020
View Locations
Clinical Trial Locations:
|
20200617140036 |
The purpose of this study is to compare any good and bad effects of using radiation to treat a meningioma that has been completely removed compared to just observing the tumor and treating it with radiation if it returns. brain;cancer;neuroscience NRG-BN003 Jennifer Barnes manderson4 Cancer Neurosciences |
||||||||
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients with Head and Neck Cancer Receiving Radiation Therapy with or without Concurrent ChemotherapyIRB Number: 2022-389
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120084943 |
<div>The overall purpose of this clinical study is to evaluate safety and</div><div>efficacy of the MuReva Phototherapy System with a light delivery</div><div>mouthpiece to reduce the severity of oral mucositis (OM) in adult</div><div>patients with squamous cell carcinoma of the oral cavity, oropharynx,</div><div>tonsils and base of tongue receiving radiation therapy with or without</div><div>concurrent chemotherapy.</div> oral mucositis, phototherapy, mureva, kane, cancer LLD-001 Jennifer Barnes Anne Kane Cancer |
||||||||
Project: Every Child, A Registry, Eligibility, Screening, Biology, and Outcome StudyIRB Number: 2015-0278
Published: May 29, 2019
View Locations
Clinical Trial Locations:
|
20190529083623 |
This study is a mechanism of maintaining a Childhood Cancer Registry which will use clinical and biological data to determine eligibility for risk stratification on therapeutic studies. The study will also be used to develop a childhood cancer repository for current and future research by collecting biospecimens at the time of diagnosis, time of progression, time of recurrence and/or post-mortem from every child diagnosed with cancer at COG institutions. The study will also allow the use of registry data for permission to be contacted in the future to consider taking part in non-therapeutic and prevention research studies involving the child and/or their parents.<br> cancer;pediatrics APEC14B1 Theresa Hutson rlong Cancer Pediatrics |
||||||||
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase IIIIRB Number: 2018-0183
Published: March 25, 2025
View Locations
Clinical Trial Locations:
|
20250325114442 |
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy. breast cancer;craft;tnbc S1501 Winona Blount bcraft Cancer |
||||||||
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (Preamble)IRB Number: 2017-0212
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528150015 |
The purpose of this study is to examine how multiple myeloma is treated by doctors all over the world, how people respond to these treatments, and the economic impact of these treatments.<br> cancer CA204-008 Lisa Freeman capayne Cancer |
||||||||
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV MelanomaIRB Number: 2024-5
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625163036 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.</span> melanoma;wilkinson;cancer EA6141 Winona Blount kjeanes Cancer |
||||||||
Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)IRB Number: 2023-408
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162914 |
This phase II/III trial compares whether cisplatin given weekly with radiation therapy is better tolerated than cisplatin given every three weeks with radiation therapy for the treatment of head and neck cancer that has spread to other places in the body (advanced). The second part of this study will also help to find out if the cisplatin given weekly approach will extend patients' life by at least the same amount of time as the cisplatin given every three weeks approach. Cisplatin is in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Radiation with low-dose cisplatin given weekly may be effective in shrinking or stabilizing head and neck cancer or preventing its recurrence. head;neck;cancer;head and neck;morgan NRG HN009 Winona Blount dpmorgan Cancer Neurosciences |
||||||||
Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway InhibitionIRB Number: 2023-402
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327093829 |
<div style="margin-top: 0.5rem; font-weight: 700; font-size: 14px; color: var(-colordark); padding-bottom: 2px; border-bottom: 1px solid var(-colorlighter); margin-bottom: 8px; text-transform: capitalize; font-family: Roboto, sans-serif; background-color: #ffffff;">Brief Summary</div><div style="box-sizing: border-box; position: relative; width: 743px; flex: 0 1 auto; font-weight: 700; font-size: 14px; color: var(-colordark); padding-bottom: 2px; border-bottom: 1px solid var(-colorlighter); margin-bottom: 8px; text-transform: capitalize; font-family: Roboto, sans-serif; background-color: #ffffff;">Detailed Description</div> prostate;prostate cancer;cancer;henegan PRESERVE-006 Winona Blount jhenegan Cancer Men's Health |
||||||||
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke CigarettesIRB Number: 2019-0046
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133606 |
<p>The purpose of this study is to see if post-operative complications can be reduced by helping participants stop smoking with a drug called Varenicline and using the NCI Tabacco Quitline for counseling. <br></p> cancer A211401 Jennifer Barnes jmoremen Cancer Lungs/Breathing |
||||||||
Registry to Evaluate Effectiveness and Safety of the Nanoknife System for the Ablation of Stage 3 Pancreatic AdenocarcinomaIRB Number: 2020-0169
Published: July 17, 2020
View Locations
Clinical Trial Locations:
|
20200717135332 |
<div>This multicenter, observational study will evaluate the</div><div>effectiveness and safety of the NanoKnife System when used</div><div>for the ablation of Stage 3 pancreatic adenocarcinoma (Stage</div><div>3 PC). Eligible patients will be recruited over a 36-month</div><div>period and participating institutions will enroll and provide</div><div>data on consecutive patients that meet inclusion and</div><div>exclusion criteria. Each patient will be followed up for the</div><div>duration of the study or until death. The study will include</div><div>two (2) cohorts: patients who received standard of care (SOC)</div><div>and received irreversible electroporation (IRE) [IRE cohort],</div><div>and patients who were treated with SOC and did not receive</div><div>IRE [SOC cohort].</div> cancer 2019-ONC-02 Sandra Powe tearl Cancer |
||||||||
RRx-001-33: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a platinum doublet or a platinum doublet in third-line or beyond small cell carcinomaIRB Number: 2018-0228
Published: July 31, 2019
View Locations
Clinical Trial Locations:
|
20190731093956 |
The purpose of this study is to look at an experimental drug that boosts the body's natural defenses to fight cancer to see if it has the potential to reduce or prevent tumors. cancer RRx001-33 Jennifer Barnes jruckdeschel Cancer |
||||||||
S1614: A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid TumorsIRB Number: 2019-0277
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712223109 |
The purpose of this study is to study the effect of tenofovir alafenamide in preventing liver complications in patients with current or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. s1416;solid tumor;entecavir;tenofovir alafenamide;tenofovir disoproxil fumarate;hepatitis b (hbv) S1416 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
S1823: A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell TumorsIRB Number: 2021-0581
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712224250 |
Studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. germ cell tumor S1823 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin LymphomaIRB Number: 2019-0206
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712225540 |
This study compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma, hodgkin disease;lymphoma S1826 Eulisa Goins-Freeman selkins Cancer |
||||||||
S1900E: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)IRB Number: 2021-0600
Published: July 19, 2022
View Locations
Clinical Trial Locations:
|
20220719114113 |
Lung MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer (NSCLC) that is stage IV or has come back (recurrent) and has a specific mutation in the KRAA gene, known as KRAS G12C. non-squamous non-small cell lung cancer;lung map;lung cancer S1900E Eulisa Goins-Freeman dpmorgan Cancer |
||||||||
S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCIRB Number: 2021-0641
Published: July 19, 2022
View Locations
Clinical Trial Locations:
|
20220719112925 |
The purpose of the study is to how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. non-small cell lung cancer;lung cancer S1914 Eulisa Goins-Freeman dpmorgan Cancer |
||||||||
S1937: A Phase III Randomized Trial of Eribulin with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyIRB Number: 2021-0584
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712233458 |
Study compares the usual chemotherapy treatment to eribulin alone to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). urothelial carcinoma S1937 Eulisa Goins-Freeman jhenegan Cancer |
||||||||
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III StudyIRB Number: 2024-9
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625160416 |
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer. craft;breast cancer;tnbc;cancer S2212 Winona Blount bcraft Cancer |
||||||||
Standard Chemotherapy versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme (GBM)IRB Number: 2018-0139
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151701 |
The purpose of this study is to screen chemotherapy drugs currently used for the care of recurrent glioblastoma (a form of brain cancer) and to determine the most effective treatment based on results from a chemosensitivity assay which is a lab test that measures the number of tumor cells that are killed by a cancer drug. <br> cancer CSCRGBM Jennifer Barnes manderson4 Cancer |
||||||||
Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)IRB Number: 2019-0049
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528133527 |
The purpose of this study is to test the good and bad effects of the study drug Rucaparib. Another purpose of this study is to learn if a biomarker test for LOH or BRCA1 or BRCA2 genes is helpful in assigning treatment.<br> cancer;preventive medicine S1900A Jennifer Barnes jruckdeschel Cancer Preventive Medicine |
||||||||
Study Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate CancerIRB Number: 2019-0078
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528113828 |
The purpose of this study is to compare any good and bad effects of using the study drug Apalutamide along with usual radiation therapy to using usual radiation therapy alone.<br> cancer;men's health NRG-GU006 Jennifer Barnes jhenegan Cancer Men's Health |
||||||||
Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction TherapyIRB Number: 2022-126
Published: November 20, 2023
View Locations
Clinical Trial Locations:
|
20231120093105 |
<span style="font-size:12.0pt;msofont-size:11.0pt;
font-family:&quot;Arial&quot;,sans-serif;msofont-family:&quot;Times New Roman&quot;;
msofont-family:&quot;Times New Roman&quot;;color:black;msolanguage:EN-US;
msolanguage:EN-US;msolanguage:AR-SA">This research study is
being done to determine if an investigational drug, called tamibarotene
(formerly SY-1425), adds any benefit in treating Newly Diagnosed Acute Myeloid
Leukemia (ND-AML) in combination with drugs called azacitidine (also known as
VIDAZA) and venetoclax (also known as VENCLEXTA) when compared to treatment
with only azacitidine and venetoclax. Only patients that are RARA-positive will
be able to be in this study.<i> </i>RARA-positive patients express high levels
of a gene called<i> RARA.</i> Tamibarotene is a targeted medication for RARA‑positive
patients. Previous studies with tamibarotene in combination with azacitidine
have shown beneficial effects in RARA-positive patients diagnosed with Acute
Myeloid Leukemia (AML). </span> tamibarotene, sy-1425, nd-aml, aml, acute myeloid leukemia, elkins, azacitidine, vidaza, venetoclax, cancer SY-1425-202 Jennifer Barnes Stephanie Elkins Cancer |
||||||||
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST TrialIRB Number: 2021-0643
Published: March 27, 2025
View Locations
Clinical Trial Locations:
|
20250327143700 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.</span> nsclc;morgan;non small cell lung cancer;non-small cell lung cancer A081801 Winona Blount dpmorgan Cancer Lungs/Breathing |
||||||||
The Caris Biorepository Research ProtocolIRB Number: 2025-232
Published: October 29, 2025
View Locations
Clinical Trial Locations:
|
20251029161907 |
<p>The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.</p><p>The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.</p> cancer;neoplasms;biospecimens TCBIO-001-0710 Winona Blount jhenegan Cancer |
||||||||
The Effect of Axoguard on Preventing Shoulder Disability Following Nerve Sparing Neck DissectionsIRB Number: 2018-0212
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528150226 |
This study will look at a protective "nerve wrap" to help reduce the amount of scar tissue that forms directly on the nerve after surgery and thereby improve shoulder range of motion, shoulder droop, shoulder pain, and overall quality of life.<br> cancer 2018-0212 Christopher Spankovich gjefferson Cancer |
||||||||
The Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung CancerIRB Number: 2018-0103
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151603 |
The purpose of this research study is to see if taking Naloxegol will help relieve pain related to Advanced Non-Small Cell Lung Cancer and will help stop the cancer from getting bigger.<br> cancer;lungs A221504 Jennifer Barnes jruckdeschel Cancer Lungs/Breathing |
||||||||
The Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MINDIRB Number: 2018-0111
Published: May 28, 2019
View Locations
Clinical Trial Locations:
|
20190528151632 |
The purpose of this research study is to compare the effects and safety of the study drug, MOR00208, given with bendamustine (BEN) to another treatment combination, rituximab (RTX) in combination with BEN to find out which combination is better for treating DLBCL.<br> cancer MOR208C204 Lisa Goins-Freeman selkins Cancer |
||||||||
TO-TAS3681-101: A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability, and Pharmacokinetic Study of TAS3681 in Patients with Metastatic Castration-Resistant Prostate CancerIRB Number: 2021-0699
Published: July 12, 2022
View Locations
Clinical Trial Locations:
|
20220712235036 |
The purpose of the study is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase). prostate cancer;tas3681 TO-TAS3681-101 Jessie Solise stang Cancer |
||||||||
UAB 2031: Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor Α PositiveIRB Number: 2024-20
Published: June 25, 2025
View Locations
Clinical Trial Locations:
|
20250625162400 |
<span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">The proposed study design is a single arm Phase II trial to document the feasibility of </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">-</span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα receptor over-expression via a centralized immunohistochemical assay (IHC) </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> identified as appropriate for study participation if IHC staining is PS2+ in >75% of cells (40% of all serous patients). Eligible patients will receive NACT with one cycle of </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">, followed by </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> + </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> (if FRα +) every 21 days for three cycles prior to interval cytoreductive surgery (iCRS). A total of 70 will be included in the study. Following completion of 4 cycles total of NACT </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> after allowing for appropriate recovery of cycle # 4, patients eligible for surgery, will undergo an iCRS. Patients will then complete 3 more cycles of </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> + </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> for a total of 7 intended cycles of treatment. It is up to the treating physician if they want to add bevacizumab to the last 2 cycles or use any type of maintenance therapy. The decision to add bevacizumab or use maintenance therapy does not need to be made upfront. Patients will sign a screening consent form prior to tissue biopsy. If a patient is found to be FRα negative, their treating physician can select the treatment they deem appropriate </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> the patient will be declared a screen failure. Patients with BRCA mutations are not excluded from this trial </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;"> are allowed to receive standard of care maintenance therapy including bevacizumab </span><span style="color: #171716; font-family: Roboto, sans-serif; background-color: #ffffff;">/or PARP inhibitors.</span> ovarian;fallopian tube;primary peritoneal;cancer UAB 2031 Winona Blount rocconi Cancer Women's Health |
||||||||
VX-20-121-102: A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation (F/MF)IRB Number: 2021-1097
Published: July 13, 2022
View Locations
Clinical Trial Locations:
|
20220713001027 |
This study is being done to learn more about the safety and effectiveness of VX-121/TEZ/D-IVA in patients with cystic fibrosis (CF). cystic fibrosis VX-20-121-102 Stephanie Moore jspurzem Genetics Lungs/Breathing |